Sophiris Bio, Inc. (OTCMKTS:SPHS) Short Interest Up 2,900.0% in May

Sophiris Bio, Inc. (OTCMKTS:SPHS) was the recipient of a large increase in short interest during the month of May. As of May 28th, there was short interest totalling 3,000 shares, an increase of 2,900.0% from the May 13th total of 100 shares. Based on an average daily volume of 73,300 shares, the days-to-cover ratio is currently 0.0 days.

SPHS remained flat at $$0.02 on Friday. The company had a trading volume of 33,560 shares, compared to its average volume of 274,139. The firm’s fifty day moving average is $0.02. Sophiris Bio has a 12-month low of $0.00 and a 12-month high of $0.07.

About Sophiris Bio

Sophiris Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the development of products for the treatment of urological diseases. The company's primary product candidate is PRX302 (topsalysin), which is in Phase III clinical trial for treatment of lower urinary tract symptoms of benign prostatic hyperplasia (BPH), as well as for the treatment of localized low to intermediate risk prostate cancer.

Recommended Story: Environmental, Social, and Governance (ESG) Investing

Receive News & Ratings for Sophiris Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio and related companies with MarketBeat.com's FREE daily email newsletter.